8-KOther EventsExhibits & Filings

BOSTON SCIENTIFIC CORP 8-K Report, Corporate Update (Jan 17, 2006)

Filed January 17, 2006For Securities:BSX

Summary

Boston Scientific Corporation (BSX) filed an 8-K on January 17, 2006, to announce a significant development in its pursuit of acquiring Guidant Corporation. The company revealed that it submitted a further revised definitive offer to Guidant on the same day. This revised offer was formally communicated via a letter from Boston Scientific's Chairman and CEO to Guidant's Chairman, indicating an ongoing and intensified effort to secure the acquisition. In conjunction with this revised offer, Boston Scientific also provided a signed merger agreement, signifying their readiness to proceed should Guidant accept the terms. This filing is crucial for investors as it highlights Boston Scientific's commitment and strategic moves in a high-stakes acquisition scenario, while also informing them about where to find additional disclosures and urging them to review forthcoming proxy statements for comprehensive details.

Key Highlights

  • 1Boston Scientific submitted a further revised definitive offer to acquire Guidant Corporation.
  • 2The revised offer was formally communicated on January 17, 2006.
  • 3A signed merger agreement, prepared by Boston Scientific, was delivered to Guidant.
  • 4This filing is categorized under 'Other Events' (Item 8.01).
  • 5The press release announcing the revised offer and the merger agreement are attached as exhibits.
  • 6Investors are urged to read future prospectus/proxy statements for important details regarding the proposed transaction.
  • 7Boston Scientific is not currently soliciting proxies for this transaction.

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly announce that Boston Scientific Corporation has submitted a further revised definitive offer to acquire Guidant Corporation and has provided a signed merger agreement.

The key documents attached as exhibits are the press release dated January 17, 2006, detailing the revised offer, and the proposed Merger Agreement that Boston Scientific is prepared to enter into with Guidant.

Investors are urged to review this filing for information on Boston Scientific's revised offer for Guidant. They should also pay close attention to future filings, specifically the prospectus/proxy statement, which will contain crucial details about the proposed transaction.

No, Boston Scientific states in the filing that they are not currently engaged in a solicitation of proxies from security holders of either Boston Scientific or Guidant in connection with the proposed acquisition.